Chronic Leukemia Panel

What is it?
Chronic Leukemia Panel is a genetic panel used for the molecular analysis of chronic leukemias. The test helps identify genetic and molecular alterations associated with the disease.

What does it analyze?
The panel analyzes genetic alterations that may be present in leukemic cells, helping with:

• identification of molecular alterations;
• genetic characterization of the disease;
• guiding the physician in determining the treatment strategy;
• evaluation of the potential response to targeted therapies.

The panel includes a combination of markers that are important for the characterization of B cells, T cells, and plasma cells, including:

• CD45 / CD14 – help with the identification and characterization of leukocyte populations.
• CD5 / CD10 / CD19 – used to characterize lymphoid populations and differentiate between different subtypes of lymphoproliferative disorders.
• FMC7 / CD23 / CD19 – help assess the immunophenotype of B cells.
• CD11c / CD34 / CD103 / CD22 / CD20 / CD25 – used for the identification and more detailed characterization of abnormal populations.
• κ / λ – assessment of the light-chain ratio helps determine the clonality of B cells.
• CD19 / CD79b – important markers for the identification and characterization of the B-cell lineage.
• CD38 / CD56 / CD138 / CD19 – used particularly for the evaluation of plasma cells and identification of abnormal populations.

When is it recommended?
It may be recommended when chronic leukemia is suspected or has been diagnosed, in order to complement the patient's hematological and molecular evaluation.

How is the sample collected?
The sample is collected according to the physician's request, usually from peripheral blood or hematological material, and analyzed using advanced molecular technologies.

Analysis
The analysis is performed using NGS (Next Generation Sequencing) technology, which enables the identification of genetic alterations relevant to the disease.

Turnaround time
The result is processed at the specialized laboratory Neuberg Diagnostics, with the turnaround time depending on the panel protocol.

 

 

FAQs

01

What is the Chronic Leukemia Panel?

 

It is an immunophenotypic panel that uses Flow Cytometry to identify and characterize abnormal hematological cell populations.

02

What diseases can it help identify?

 

It is primarily used in the evaluation of chronic leukemias and lymphoproliferative disorders, particularly those involving B cells.

03

What markers does it analyze?

 

The panel includes markers such as CD45, CD5, CD10, CD19, FMC7, CD23, CD20, CD22, CD34, CD38, CD56, CD138, CD79b, κ/λ, and others.

04

Is it used for the diagnosis of CLL?

 

Yes. Immunophenotyping by Flow Cytometry is an important part of the evaluation of Chronic Lymphocytic Leukemia (CLL).

05

How is the sample collected?

 

Depending on the clinical case, the analysis can be performed using peripheral blood or a bone marrow aspirate.

06

Is it the same as the IgVH (CLL) test?

 

No. The Chronic Leukemia Panel is an immunophenotypic analysis performed using Flow Cytometry, whereas IgVH (CLL) is a molecular test that determines the mutational status of the IGHV gene.

07

Is this test sufficient to establish a diagnosis?

 

The results are interpreted together with other hematological tests, clinical findings, and, when necessary, molecular or cytogenetic tests.

08

Who should recommend the test?

 

The test should be recommended and interpreted by a hematologist based on the patient's medical history and test results.